↓ Skip to main content

Updates on cardiovascular outcome trials in diabetes

Overview of attention for article published in Cardiovascular Diabetology, October 2017
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (70th percentile)

Mentioned by

twitter
9 tweeters

Citations

dimensions_citation
43 Dimensions

Readers on

mendeley
102 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Updates on cardiovascular outcome trials in diabetes
Published in
Cardiovascular Diabetology, October 2017
DOI 10.1186/s12933-017-0610-y
Pubmed ID
Authors

Oliver Schnell, Lars Rydén, Eberhard Standl, Antonio Ceriello

Abstract

In 2008 the Food and Drug Administration introduced a guidance for industry that requires the investigation of cardiovascular outcomes of glucose-lowering medications. Since then, an increasing number of cardiovascular outcome trials have been completed in diabetes patients with high cardiovascular risk for members of the SGLT-2 and DPP4 inhibitors and GLP-1 receptor agonist classes. The trials confirmed cardiovascular safety for all tested anti-hyperglycaemic drugs and, in addition empagliflozin, semaglutide and liraglutide could even reduce cardiovascular risk. The present review summarizes the results of the DEVOTE, CANVAS, EXSCEL and ACE trials that tested cardiovascular safety of Insulin degludec, canagliflozin, once-weekly exenatide and acarbose and were published in 2017. We provide context on these results by comparing them with earlier trials of glucose-lowering drugs and give an outlook on what to expect in coming years.

Twitter Demographics

The data shown below were collected from the profiles of 9 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 102 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 102 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 17 17%
Student > Master 15 15%
Other 13 13%
Student > Bachelor 11 11%
Student > Ph. D. Student 8 8%
Other 21 21%
Unknown 17 17%
Readers by discipline Count As %
Medicine and Dentistry 54 53%
Pharmacology, Toxicology and Pharmaceutical Science 8 8%
Biochemistry, Genetics and Molecular Biology 6 6%
Nursing and Health Professions 2 2%
Mathematics 2 2%
Other 6 6%
Unknown 24 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 September 2018.
All research outputs
#4,987,946
of 19,101,906 outputs
Outputs from Cardiovascular Diabetology
#271
of 1,103 outputs
Outputs of similar age
#85,022
of 292,306 outputs
Outputs of similar age from Cardiovascular Diabetology
#1
of 1 outputs
Altmetric has tracked 19,101,906 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 1,103 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.9. This one has done well, scoring higher than 75% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 292,306 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them